INS and Alzheimer disease: For instance, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, which enhance insulin secretion and reduce glucagon release, have shown promise in preclinical AD models and are now in clinical trials (Atri et al. 2022; Edison et al. 2021).